Rare Disease News and Research

RSS

Discovery of mechanism and possible drug treatment for growth of nerve tumors in neurofibromatosis

Researchers studying neurofibromatosis type 1 - a rare disease in which tumors grow within nerves - have found that the tumors are triggered by crosstalk between cells in the nerves and cells in the blood.

30 Oct 2008

FDA grants approval to Talecris Biotherapeutics for Gamunex for neurological disorder CIDP

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills.

15 Sep 2008

Woman dies after being scratched by a wild rat

As a rule leptospirosis victims experience severe headaches and flu-like symptoms but the severe form which is Weil's disease, causes jaundice and liver damage, and can be fatal - but it usually only affects 10% of leptospirosis victims.

15 Sep 2008

FDA approves Gamunex for chronic inflammatory demyelinating polyneuropathy

The U.S. Food and Drug Administration has announced that it has approved an immune globulin product called Gamunex for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.

14 Sep 2008

Low levels of 'brain derived neurotrophic factor' may lead to obesity

A brain chemical that plays a role in long term memory also appears to be involved in regulating how much people eat and their likelihood of becoming obese, according to a National Institutes of Health study of a rare genetic condition.

28 Aug 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Alternative vaccine strategy shows promise in prostate cancer patients

New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. 15, 2008, issue of Clinical Cancer Research.

17 Aug 2008

Researchers find Leishmaniasis parasites evade death by exploiting the immune response to sand fly bites

Cutaneous leishmaniasis, a disease characterized by painful skin ulcers, occurs when the parasite Leishmania major, or a related species, is transmitted to a mammalian host by the bite of an infected sand fly.

14 Aug 2008

In-depth review of current research on the health effects of vitamin D

Despite considerable progress in research to understand the health effects of vitamin D, experts convened by the NIH to review the available data found major gaps in the evidence. The data are strongest in the area of bone health among elderly men and post-menopausal women, suggesting that increased vitamin D intake can improve bone health and prevent falls. For other age groups and health issues, though, it is too early to say conclusively whether more vitamin D might be beneficial.

12 Aug 2008

Cancer Research UK expresses 'deep concern' on kidney cancer drug decision

Cancer Research UK - the largest publicly funded research charity in the UK - wants to see the way NICE review the value of drugs altered for rare diseases, such as this type of kidney cancer, where clinical benefit is proven but evidence is limited.

8 Aug 2008

Scientists discover link between DNA copy number changes and cancer risk

Scientists at The Hospital for Sick Children (SickKids) have discovered a link between a newly discovered form of inherited genetic alteration, termed DNA copy number variation (CNV), and cancer susceptibility.

4 Aug 2008

Scientists develop ultra-sensitive optical protein sensor, a first for a salivary diagnostic test

For people who dislike needles, medical tests that require a drop of saliva instead of a vial of blood will one day make a trip to a doctor or dentist much easier. But as scientists now construct the first of these saliva tests for early signs of cancer and other diseases, they continue to push the technological envelope in interesting ways.

3 Aug 2008

Treatment delays result in poor outcomes for men with breast cancer

Men who develop breast cancer are often not treated until the disease has spread to the point that treatment becomes difficult, new results show.

6 Jul 2008

Yeast-based vaccine induces immune responses and reduces tumor size in mice

Scientists have found that vaccination with a heat-killed, non-toxic yeast that is genetically engineered to manufacture a common tumor protein can induce specific and repeated anti-tumor immune responses in mice.

1 Jul 2008

Broad differences in alcohol, tobacco and illegal drug use across countries

A survey conducted by the World Health Organization (WHO) research consortium found that the United States had among the highest lifetime rates of tobacco and alcohol use and led in the proportion of participants reporting cannabis (marijuana) or cocaine use at least once during their lifetime.

1 Jul 2008

Distinct clusters of genetic markers linked to treatment responses for smoking cessation

Scientists have identified distinct clusters of genetic markers associated with the likelihood of success or failure of two smoking cessation treatments, nicotine replacement therapy (NRT) and the medication bupropion (Zyban). This study, supported by the National Institute on Drug Abuse (NIDA) and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), was published in the June issue of the journal Archives of General Psychiatry.

2 Jun 2008

NIDA highlights best drug abuse treatment approaches at blending conference

The most difficult challenge in finding substance abuse treatment for a loved one is how to know which programs have a proven track record. That is just one of the topics being discussed today at the conference "Blending Addiction Science and Treatment: The Impact of Evidence-Based Practices on Individuals, Families and Communities." Held at the Duke Energy Center in Cincinnati, the conference is hosted by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. It is part of NIDA's Blending Initiative, in which teams of experts create clinical tools based on the latest treatment research.

2 Jun 2008

Spontaneous mutations widespread in non-familial schizophrenia

People with schizophrenia from families with no history of the illness were found to harbor eight times more spontaneous mutations - most in pathways affecting brain development - than healthy controls, in a study supported in part the National Institutes of Health?s (NIH) National Institute of Mental Health (NIMH). By contrast, no spontaneous mutations were found in people with schizophrenia who had family histories of the illness.

30 May 2008

Rett syndrome gene found to be full of surprises

A study funded by the National Institutes of Health (NIH) has transformed scientists' understanding of Rett syndrome, a genetic disorder that causes autistic behavior and other disabling symptoms. Until now, scientists thought that the gene behind Rett syndrome was an "off" switch, or repressor, for other genes. But the new study, published today in Science, shows that it is an "on" switch for a startlingly large number of genes.

29 May 2008

Scientists identify a brain mechanism underlying persistent cocaine craving

Scientists have identified a mechanism in the brain that helps to explain why craving for cocaine, and the risk of relapse, seems to increase in the weeks and months after drug use is stopped. The research was supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

28 May 2008